Gradalis® - Personalized Cancer Immunotherapy Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer
The Vigil Platform | Gradalis® At Gradalis, we’re committed to researching and developing individualized cancer products as unique as the patients we serve That’s why we developed Vigil—a personalized cancer immunotherapy that uses your own immune system to recognize, target, and fight cancer in a way that traditional, one-size-fits-all treatments cannot
Company | Gradalis® She is responsible for leading Gradalis’ project management, clinical, regulatory and data services She oversees regulatory clinical research projects, safety reporting for oncology, and provides the project team with guidance, training and strategic planning
News - Gradalis® Gradalis Announces Publication in Clinical Cancer Research Featuring Positive Results from a Study Evaluating Vigil® in Combination Therapy for Patients with Recurrent Ewing's Sarcoma
Clinical Trials - Gradalis® Gradalis Clinical Trials Vigil is a personalized cancer immunotherapy utilizing the patient’s own tumor cells
How It Works | Vigil by Gradalis® Vigil is a fully personalized, patient-specific cancer immunotherapy that can be applied to virtually any cancer from which a surgical sample can be gathered
Careers - Gradalis® Gradalis is an integrated biotechnology company based in Dallas, Texas, focused on revolutionizing cancer treatment through the development, manufacture, and commercialization of personalized therapeutics to treat cancer
Key Publications | Gradalis® Gradalis uses cookies to improve your experience on this website Some of the cookies we use are essential for parts of the website to operate Please be aware that if you continue without changing your cookie settings, you consent to this For more information on our use of cookies, please review our cookie policy
Terms Conditions | Gradalis® Gradalis spends significant dollars each year in discovery, development, acquisition and protection of its technology Much of the Company's technology is protected by U S and foreign patents